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Abstract
Arterial tortuosity syndrome (ATS) is an autosomal recessive connective tissue disorder caused by loss-of-function mutations
in SLC2A10, which encodes facilitative glucose transporter 10 (GLUT10). The role of GLUT10 in ATS pathogenesis remains an
enigma, and the transported metabolite(s), i.e. glucose and/or dehydroascorbic acid, have not been clearly elucidated. To
discern the molecular mechanisms underlying the ATS aetiology, we performed gene expression proﬁling and biochemical
studies on skin ﬁbroblasts. Transcriptome analyses revealed the dysregulation of several genes involved in TGFβ signalling
and extracellular matrix (ECM) homeostasis as well as the perturbation of speciﬁc pathways that control both the cell energy
balance and the oxidative stress response. Biochemical and functional studies showed a marked increase in ROS-induced
lipid peroxidation sustained by altered PPARγ function, which contributes to the redox imbalance and the compensatory
antioxidant activity of ALDH1A1. ATS ﬁbroblasts also showed activation of a non-canonical TGFβ signalling due to TGFBRI
disorganization, the upregulation of TGFBRII and connective tissue growth factor, and the activation of the αvβ3 integrin
transduction pathway, which involves p125FAK, p60Src and p38 MAPK. Stable GLUT10 expression in patients’ ﬁbroblasts
normalized redox homeostasis and PPARγ activity, rescued canonical TGFβ signalling and induced partial ECM re-organization.
These data add new insights into the ATS dysregulated biological pathways and deﬁnition of the pathomechanisms involved
in this disorder.
Introduction
Arterial tortuosity syndrome (ATS; OMIM #208050) is a rare auto-
somal recessive connective tissue disorder (CTD) characterized
by the tortuosity and elongation of large- and medium-sized
arteries. The main cardiovascular features include arterial and
pulmonary valve stenosis, a propensity towards aneurysm forma-
tion and vascular dissection, aberrant origin of aortic branches,
and vasomotor instability. ATS also shows additional signs shared
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withotherCTDs, including soft/velvety/hyperextensible skin,mild
dysmorphic facial features, i.e. elongated face, hypertelorism, cleft
palate and/or biﬁd uvula, and micro/retrognathia, abdominal
hernias, joint hypermobility and instability (1–8).
ATS is caused by mutations in the SLC2A10 gene, which en-
codes the 541-amino acid facilitative glucose transporter 10
(GLUT10) (3). GLUT10 belongs to the SLC2A transporter family,
the members of which facilitate uptake of several substrates,
including glucose, galactose, fructose, mannose, glucosamine,
urate and dehydroascorbic acid (DAA) (9,10). In vitro-grown
ATS skin ﬁbroblasts and aortic vascular smooth muscle cells
(AVSMCs) do not organize the GLUT10 in plasma and intracellular
membranes (3).
Twenty-three SLC2A10 genemutations have been reported (8).
Although the pathogenic mechanism underlying the SLC2A10
mutations is clearly a loss of function, the speciﬁc role of
GLUT10 in the ATS aetiology remains an enigma. Mouse models
failed to recapitulate the ATS vascular phenotype because vascu-
lar abnormalities were absent in mice with Slc2a10 homozygous
missense substitutions (11,12). The zebraﬁsh model better high-
lighted the essential role of GLUT10 in cardiovascular develop-
ment because knockdown of the slc2a10 orthologue, which is
broadly expressed during embryogenesis (13), was associated
with several cardiovascular defects (14).
Loss of function of SLC2A10 activates TGFβ signalling (3,15,16).
Induction of the TGFβ pathway was indicated by the enhanced
expression of the connective tissue growth factor (CTGF) in ATS
arterial tissue and by the reduced expression of decorin (DCN),
which is a TGFβ signalling inhibitor proteoglycan, in in vitro
cultured ATS cells (3). ATS is associated with abnormal collagens
(COLLs) and elastin (ELN) synthesis (3), due to the key role of TGFβ
signalling in extracellular matrix (ECM) ﬁbrillogenesis and
homeostasis. The importance of GLUT10 in facilitating TGFβ
signalling was also indicated by comparing slc2a10 zebraﬁsh
morphants with TGFBR1 receptor-inhibited embryos, which are
phenocopies that exhibit the same cardiovascular abnormalities,
such as a wavy notochord as well as incomplete and irregular
vascular patterning (14).
In the last years, increasing evidence indicates that GLUT10
might act as an intracellular transporter of DAA, which is the
oxidized form of ascorbic acid (AA) (10,17,18). As an antioxidant,
AA protects against oxidative stress-induced cellular damage by
scavenging free radicals and reactive oxygen species (ROS),
neutralizing by a vitamin E-dependent way lipid hydroperoxyl
radicals, and protecting proteins from alkylation using electro-
philic lipid peroxidation (LPO) products (19). Furthermore, AA
is an essential cofactor for α-ketoglutarate-dependent dioxy-
genases (10). Segade used rat aortic smooth muscle cells to
show GLUT10 colocalization with the rough endoplasmic
reticulum (ER), wherein proline and lysine residues are hydroxy-
lated, and COLLs and ELN are prepared for secretion by the Golgi
apparatus. Thus, the author hypothesized that the loss of
GLUT10 in ATS decreases DAA uptake by the ER, which yields
an inadequate level of available AA for prolyl and lysyl hydroxy-
lases inside the ER as well as synthesis and extracellular depos-
ition of abnormal COLL and ELN (17). AA regulates the activity
of many AA-dependent dioxygenases also in the nucleus,
such as ten-eleven translocation demethylases and the Jumonji
protein family, which catalyse epigenetically relevant reactions,
including nucleic acid demethylation and histone demethyla-
tion/hydroxylation (10). Based on these data, Bánhegyi and
coworkers hypothesized that DAA could enter the nucleus
from a pool of DAA in the nuclear envelope (NE), which is a sub-
domain of the ER, through GLUT10, which is located either in the
ER membrane or the inner membrane of the NE (10). In ATS, ab-
normal AA nuclear homeostasis, due to the lack of GLUT10,
should lead to altered gene expression.
Lee and colleagues showed that GLUT10 localized to mito-
chondria in mouse AVSMCs, where it enhanced DAA uptake,
which was accompanied by a decrease in ROS levels in H2O2-
treated cells, and suggested that GLUT10 protects cells from
ROS-induced vascular damage (18). Despite these ﬁndings, a re-
cent study suggested that GLUT10 is not likely to be present in
mitochondria because this transporter got far the lowest mito-
chondrial localization scores using in silico prediction tools (20).
Moreover, mitochondrial AA transport should not depend on
GLUT10 because it is mainly mediated by a low-afﬁnity form of
the sodium-coupled ascorbic acid transporter-2 (21). Overall,
the dependence of AA availability in the ER, in the nucleus, and
in the mitochondria on GLUT10 activity and its relevance to
ATS remains to be demonstrated.
For insight into the ATS pathomechanisms, we used skin ﬁ-
broblasts from healthy donors and ATS patients, grown in me-
dium containing fetal bovine serum (FBS) as the only source of
AA, in a combined approach using transcriptome, biochemical
and functional studies. Our results revealed that the GLUT10
deﬁciency alters energetic/redox homeostasis and activates
non-canonical TGFβ signalling, which involves TGFBRII, and the
αvβ3 integrin transduction pathway, in association with the ECM
disarray.
Results
Lackof GLUT10 expression is associatedwith the disarray
of several structural ECM components in ATS ﬁbroblasts
Three ATS ﬁbroblast strains derived from patients with different
SLC2A10mutations were analysed for GLUT10 expression. Indir-
ect immunoﬂuorescence (IF) analysis showed that the protein
was abundantly expressed by control skin ﬁbroblasts, whereas
it was undetectable in the ATS cells regardless of the SLC2A10
mutation type (Fig. 1). Western blotting (WB) analysis conﬁrmed
these results (data not shown). To validate the association of
GLUT10 deﬁciency with ECM disarray, we used IF to investigate
the organization of different structural proteins, type III COLL
(COLLIII), type V COLL (COLLV), ELN, all of the ﬁbrillin isoforms
(FBNs) and DCN. As shown in Figure 1, ELN was organized in a ﬁ-
brillar network covering 7-day-grown control ﬁbroblasts, where-
as it was not assembled into the ECM of ATS cells, which retained
this protein at different levels in the cytoplasm also after 15 days
of culture (data not shown). ATS ﬁbroblasts did not organize
FBNs, COLLIII, COLLV and DCN in the ECM. In particular, only a
few FBN ﬁbrils were localized in the intercellular spaces; all of
the COLLs investigated were retained in the cytoplasm, and
DCN was almost undetectable in all of the ATS patients’ cells.
These results demonstrate that GLUT10 deﬁciency is associated
with the disassembly of several ECM components, which high-
lights the key role of this transporter in ECM homeostasis.
Transcriptome-wide expression proﬁling of ATS skin
ﬁbroblasts shows differentially expressed genes that
inﬂuence lipid metabolism, intracellular redox
homeostasis and ECM maintenance
To screen for candidate genes that may contribute to ATS patho-
genesis, we performed a transcriptome-wide expression ana-
lysis, wherein we compared the gene expression patterns of
three ATS patients’ skin ﬁbroblasts with those of ﬁbroblasts
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from three healthy individuals. We identiﬁed 217 differentially
expressed genes (DEGs) in the patients by applying a fold-change
threshold greater than or equal to ±1.5 with an uncorrected
P < 0.05. In particular, 112 genes were signiﬁcantly upregulated,
and 105 were signiﬁcantly downregulated (Supplementary
Material, Table S1). Table 1 shows a selection of the up- and
downregulated transcripts. A scatter plot for all of themicroarray
data and a heatmap for the DEGs are shown in Supplementary
Material, Figure S1. Although ﬁbroblasts from only three control
subjects and three ATS patients were investigated, this analysis
showed the presence of two distinct clusters of transcripts that
clearly distinguish themutant from control cells, which indicates
relative low variability within each group and demonstrates that
our ﬁndings are statistically signiﬁcant.
To identify the biological processes that are over- or underre-
presented in GLUT10-deﬁcient ﬁbroblasts, we grouped the DEGs
according to the Gene Ontology (GO) categories using DAVID
functional annotation clustering and selecting only terms with
P ≤ 0.05 and ≥3 genes in each annotation term. An enrichment
analysis for the 112 upregulated genes generated 21 distinct
clusters (Supplementary Material, Table S2A). Among the differ-
ent GO clusters, themost enriched genes involved in “lipidmeta-
bolic process” and “response to organic substance” were PPARG,
PLA2G4A, IGFBP2, ALPL, ADCY4 and ACTC1 and in “oxidation
reduction process” and “response to ROS” were ALDH1A1,
CYP2U1, FAR2,ADH1C, FADS2, SOD3 and PLA2G4A. Among the up-
regulated genes, ALDH1A1 encodes the aldehyde dehydrogenase
(ALDH) family 1 member A1 (ALDH1A1) involved in retinoic acid
metabolism and LPO-derived reactive aldehyde detoxiﬁcation
(22,23). PPARG, FAR2, FADS2, CYP2U1 and PLA2G4A are involved
in the PPAR signalling pathwayand fatty acidmetabolism. In par-
ticular, FAR2 encodes a fatty-acyl-CoA reductase 2,which is a per-
oxisomal enzyme involved in the long-chain fatty-acyl-CoA
metabolic process (24). The fatty acid desaturase FADS2 is in-
volved in alpha-linolenic (ω-3) and linoleic (ω-6) acid metabolism
(25). The phospholipase PLA2G4A catalysesmembrane phospho-
lipid hydrolysis to release arachidonic acid, which ismetabolized
into eicosanoids (26). PPARG is amember of the nuclear hormone
receptor superfamily that acts as a ligand-activated transcription
factor and is a master regulator in a range of physiological and
Figure 1. Expression of GLUT10 and ECM organization in control and ATS ﬁbroblasts. IF of GLUT10 in control and ATS ﬁbroblasts grown for 48 h and immunoreacted with
anti-GLUT10 Ab. Scale bar, 4 µm. IF of ELN, FBNs, COLLIII, COLLV and the core protein of DCN organized in the ECMwas performed for the control and ATS ﬁbroblasts 48 h
after seeding or 7 days after seeding for ELN using the speciﬁc Abs. Scale bar: 10.8 µm. The experiments were repeated three times. The images are representative of two
control (C1 and C2) and the three ATS cell strains (P1, P2, and P3).
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pathophysiological events, including vascular remodelling, adi-
pogenesis, insulin action stimulation, lipid metabolism regula-
tion, mitochondrial and redox homeostasis maintenance, and
inﬂammatory processes (27).
A functional analysis of 105 downregulated genes yielded
20 different clusters (Supplementary Material, Table S2B). The
signiﬁcantly downregulated processes include genes related to
ECM homeostasis, i.e. LOXL4, IL6, TNXB, COMP, MMP7, TGFA and
PDGFC; genes with transcription regulator activity, i.e. EGR3,
TSHZ2, TSHZ1, TBX5, HOXA11, MSX2, ACVR2A and HOXA7; genes
related to regulating cell proliferation, i.e. IL6, TNFSF4, TBX5,
MSX2,TGFA andPDGFC; andgenes related toblood vesselmorpho-
genesis and heart development, i.e. MSX2, SMAD7, HAND2, TBX5,
EMCN, TGM2 and TGFA. Processes related to regulating apoptosis,
signal transduction and phosphatemetabolic processes were also
underrepresented. Among the downregulated genes, LOXL4
encodes an extracellular copper-dependent amine oxidase that
catalyses the ﬁrst step in cross-link formation in COLL and ELN,
and TGM2 encodes a member of the transglutaminase enzyme
family that plays a role in ECM remodelling (28,29). A pathway
enrichment analysis performed using all of the DEGs conﬁrmed
that the GLUT10 deﬁciency perturbs several functions that are
mainly involved in ECM homeostasis (Supplementary Material,
Table S2C).
Quantitative real-time PCR (qPCR) was performed on a selec-
tion of genes involved in ECM homeostasis and TGFβ signalling,
i.e. LTBP1, TGM2, CCBE1, TNXB, DCN, LOXL4, IL-6, ITGB8 and COMP,
and in different metabolic processes, i.e. ALDH1A1, FADS2, FAR2,
IGFBP2, PPARG, PLA2G4A and RARB. The data conﬁrmed the reli-
ability of the microarray data because the above-reported genes
were differentially expressed (Fig. 2A and B). Although the array
did not indicate the differential expression of DCN, which is a
Table 1. Selection of DEGs in ATS ﬁbroblasts.
RefSeq Gene symbol Gene description Fold change
Upregulated genes
NM_000689 ALDH1A1 Aldehyde dehydrogenase 1 family, member A1 9.83738
NM_005159 ACTC1 Actin, alpha, cardiacmuscle 1 4.75185
NM_018099 FAR2 Fatty-acyl-CoA reductase 2 4.50713
NM_000965 RARB Retinoic acid receptor, beta 3.87470
NM_003206 TCF21 Transcription factor 21 3.84177
NM_000597 IGFBP2 Insulin-like growth factor-binding protein 2 3.69562
NM_006547 IGF2BP3 Insulin-like growth factor 2 mRNA-binding protein 3 3.64178
NM_024420 PLA2G4A Phospholipase A2, group IVA (cytosolic, calcium-dependent) 3.56846
NM_138712 PPARG Peroxisome proliferator-activated receptor gamma 3.43780
NM_032961 PCDH10 Protocadherin 10 3.32056
NM_000921 PDE3A Phosphodiesterase 3A, cGMP-inhibited 3.03603
NM_181458 PAX3 Paired box 3 3.02732
NM_133459 CCBE1 Collagen and calcium-binding EGF domains 1 2.95478
NM_001957 EDNRA Endothelin receptor type A 2.93793
NM_021110 COL14A1 Collagen, type XIV, alpha 1 2.50414
NM_001144996 ITGA7 Integrin, alpha 7 2.30934
NM_021219 JAM2 Junctional adhesion molecule 2 2.21089
NM_206943 LTBP1 Latent transforming growth factor beta-binding protein 1 2.18537
NM_004265 FADS2 Fatty acid desaturase 2 2.06592
NM_145176 SLC2A12 Solute carrier family 2 (facilitated glucose transporter), member 12 1.88461
NM_005328 HAS2 Hyaluronan synthase 2 1.80415
NM_000669 ADH1C Alcohol dehydrogenase 1C (class I), gamma polypeptide 1.79118
NM_001080508 TBX18 T-box 18 1.78918
NM_002207 ITGA9 Integrin, alpha 9 1.70987
Downregulated genes
NM_181486 TBX5 T-box 5 −5.38536
NM_003326 TNFSF4 Tumour necrosis factor (ligand) superfamily, member 4 −4.52814
NM_002016 FLG Filaggrin −3.53054
NM_000561 GSTM1 Glutathione S-transferase mu 1 −3.42929
NM_000095 COMP Cartilage oligomeric matrix protein −3.13002
NM_000600 IL6 Interleukin 6 (interferon, beta 2) −2.98091
NM_003266.3 TLR4 Toll-like receptor 4 −2.80100
NM_198148 CPXM2 Carboxypeptidase X (M14 family), member 2 −2.74518
NM_000782 CYP24A1 Cytochrome P450, family 24, subfamily A, polypeptide 1 −2.68277
NM_016352 CPA4 Carboxypeptidase A4 −2.67307
NM_004613 TGM2 Transglutaminase 2 −2.62830
NM_002214 ITGB8 Integrin, beta 8 −2.47052
NM_032211 LOXL4 Lysyl oxidase-like 4 −2.10516
NM_017993 ENOX1 Ecto-NOX disulﬁde-thiol exchanger 1 −1.80740
NM_173354 SIK1 Salt-inducible kinase 1 −1.75467
NM_032470 TNXB Tenascin XB −1.75391
NM_003236 TGFA Transforming growth factor, alpha −1.71934
NM_005904 SMAD7 SMAD family member 7 −1.55245
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proteoglycan involved in COLL ﬁbrils formation and the regulation
of TGFβ bioavailability, we analysed it using qPCR and demon-
strated that it was signiﬁcantly downregulated (Fig. 2A). Other
dysregulated genes that enter the TGFβ pathway include LTBP1,
which encodes a member of the latent-binding protein family,
and ITGB8, which encodes the β8 integrin subunit involved in
Figure 2.Validation ofmicroarrayexpression data by qPCR. Relative quantiﬁcation (RQ) of selected genes related to ECMorganization and TGFβ signalling (A) and involved
in different metabolic processes (B) was generated using the 2−(ΔΔCt) method and normalized using the geometric mean of the HPRT, GAPDH, CYC1, ATP5B and RPLP0
reference genes. The expression levels of selected miRNAs (C) was calculated using RNU66 as an internal normalization transcript. The bars represent the mean ratio
of the target gene/miRNA expression in patients’ ﬁbroblasts compared with three unrelated healthy individuals. qPCR was performed in triplicate, and the results are
expressed as the mean ± SEM. In (A) and (C), the relative expression levels of the target genes/miRNA in patients versus controls were expressed as the
non-transformed relative fold change. In (B), the log 2 transformed values are shown. Statistical signiﬁcance was determined using an unpaired Student’s t-test or the
one-way ANOVA followed by Tukey’s post hoc test (*P < 0.05 and **P < 0.01).
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integrin-mediated activation of TGFβ. TNXB encodes a member of
the tenascins family (TN-X) that regulates elastic ﬁbre structure
and stability, COLL synthesis and deposition in the ECM, and
TGFβ bioavailability (30). Similarly, COMP, which encodes a non-
collagenous ECM glycoprotein that binds several COLLs, ﬁbro-
nectin (FN), and aggregan, regulates TGFβ bioavailability (31).
Together, the transcriptome-wide expression proﬁling results in-
dicate that SLC2A10 mutations perturb many physiological pro-
cesses related to energetic/redox homoeostasis, TGFβ signalling
maintenance, and ECM architecture.
We also analysed the global expression levels of miRNAs in
the three ATS patients’ skin ﬁbroblasts. By selecting a ≥1.5-fold-
change threshold relative to the controls, 30 miRNAs showed a
differential expression patterns: 15 were upregulated and 15
were downregulated (Supplementary Material, Table S3). The
most upregulated miRNA was hsa-miR-505. Interestingly, this
miRNA was upregulated in dissected aortic tissues, which sug-
gests that its altered expression plays an essential role in aortic
dissection pathogenesis (32). We compared the DEG list with
the differentially expressedmiRNAs to investigate a possible cor-
relation between the expressed miRNA and mRNA in ATS cells
(see Supplementary Material, Table S4 for a full list of the
miRNA-mRNA interactions). This analysis showed that the up-
regulated hsa-miR-505, hsa-miR-148b and hsa-miR-4708-5p
miRNA might regulate the level of transcription for many down-
regulated ECM genes, i.e. TGM2, ITGB8, LOXL4 and TNXB. On the
other hand, the downregulated hsa-miR-34c-3p, hsa-miR-339-
3p and hsa-miR-200c miRNAs have as potential targets several
upregulated DEGs related to metabolic processes and ECM
remodelling, i.e. ALDH1A1, PLA2G4A, LTBP1 and CCBE1 (Sup-
plementary Material, Table S4). qPCR validation conﬁrmed the
differential expression pattern of a selection of miRNAs in ATS
cells, i.e. hsa-miR-505, hsa-miR-148b, hsa-miR-34c-3p and hsa-
miR-339-3p (Fig. 2C). The modulation of the expression levels of
several miRNAs and the compelling correlation between
miRNA-DEG levels suggests that epigenetics may be involved in
the altered gene expression observed in GLUT10-deﬁcient cells,
which merits future investigation.
ATS ﬁbroblasts show increased synthesis of ALDH1A1
and PPARγ as well as ROS-induced oxidative stress
The expression levels and activity of ALDH1A1, which is encoded
by the most upregulated gene in the ATS cells versus the control
ﬁbroblasts, were investigated by IF, WB and ﬂow cytometry
(Fig. 3). Using IF, cytosolic ALDH1A1was not well detected in con-
trol ﬁbroblasts, but it was highly expressed in ATS cells (Fig. 3A).
These resultswere conﬁrmed byWB (Fig. 3B) and by the Aldeﬂuor
assay, which showed ∼3-fold higher ALDH activity in the ATS
cells versus the controls (Fig. 3C and Supplementary Material,
Fig. S2). Because the other two ALDH isoforms, i.e. ALDH1A2
and ALDH1A3, were expressed in the ATS cells and control ﬁbro-
blasts at comparable levels (data not shown), the enhancedALDH
activity in ATS cells is mainly attributed to ALDH1A1.
We further studied PPARγ using IF and WB. As shown in
Figure 3A, PPARγ, which is not well detected in control cells,
was highly expressed in the cytoplasm and in the perinuclear re-
gion of ATS ﬁbroblasts. The increased PPARγ expression in ATS ﬁ-
broblasts was conﬁrmed by WB, which showed high levels of a
53 kDa band corresponding to PPARγ1, which was almost un-
detectable in the controls, and a 57 kDa band corresponding to
PPARγ2, which was not well detected in the control ﬁbroblasts
(Fig. 3B). PPARγ undergoes several post-translational modiﬁca-
tions (PTMs) in response to exogenous signals, such as growth
factors and adipokines, which modulate its functions. The
most well-described PTM is PPARγ2 phosphorylation at Ser112
(pS112-PPARγ) (corresponding to Ser82 in PPARγ1) (33), which we
investigated by IF and WB (Fig. 3A and B) using a speciﬁc poly-
clonal antibody (Ab) that recognizes both phosphorylated iso-
forms. The ATS cells showed higher levels of pS112-PPARγ than
the control cells, and elevated PPARγ signalling should be acti-
vated in ATS ﬁbroblasts because the protein is mainly translo-
cated to the nucleus.
To validate that the GLUT10 deﬁciency is associated with the
alteration of the intracellular redox homeostasis, we analysed
both in control and ATS ﬁbroblasts the ROS levels using the Cell-
ROX® Green assay. As shown in Figure 4, high ROS levels were de-
tected in ATS cells, but ROS activity was not observed in the
control ﬁbroblasts without adding the ROS-speciﬁc pro-oxidant
agent tert-butyl hydroperoxidase (TBHP) (Supplementary Mater-
ial, Fig. S3). To investigate the possible involvement of PPARγ in
the ROS overproduction observed in ATS cells, we inhibited
PPARγ activity using the selective antagonist T0070907 at sub-
lethal concentrations, 1.0–2.5 µM. After inhibiting either control
or ATS ﬁbroblasts, we evaluated the pS112-PPARγ distribution
and the ROS levels. As shown in Supplementary Material,
Figure S4, the antagonist signiﬁcantly reduced the levels of the
nuclear pS112-PPARγ in a dose-dependent manner; in particular,
the nuclear receptorwas undetectable in both cell types at 2.5 μ.
At this optimal inhibition dose, the control ﬁbroblasts showed a
marked increase in ROS production, which conﬁrmed that PPARγ
attenuates oxidative stress under physiological conditions by in-
ducing antioxidant pathways (27). In ATS cells, PPARγ inhibition
elicited the opposite effect because it was associated with a
marked decrease in ROS levels. This result suggests that aberrant
activity of PPARγ in ATS cells, likely linked to Ser112 phosphoryl-
ation, contributes to oxidative stress-induced injury, which mer-
its future investigation.
The elevated ROS levels identiﬁed in ATS ﬁbroblasts indicate
that these cells are under oxidative stress and suggest an
enhanced ROS-induced LPO process, which may explain the
induction of ALDH1A1. To validate this hypothesis, LPO was
investigated both in the control and ATS cells using the Click-
iT® LPO detection kit with linoleamide alkyne (LAA). ATS ﬁbro-
blasts showed high levels of LPO-derived adducts (Fig. 4, +LAA),
whereas these modiﬁcations were undetectable in the control
cells without adding the LPO-speciﬁc pro-oxidant compound
cumene hydroperoxide (Supplementary Material, Fig. S3).
Furthermore, in ATS cells, the LPO-derived modiﬁcations were
measurable even without adding the speciﬁc substrate LAA
(Fig. 4, −LAA), and the levels of these adducts were higher than
in cumene hydroperoxide-treated control cells (Supplementary
Material, Fig. S3). These results suggest that a GLUT10 deﬁciency
is associated with the hyperactivation of the ROS-induced LPO
process in ATS cells, which is likely sustained by the enhanced
lipid metabolism that upregulates ALDH1A1 as a compensatory
mechanism to attenuate oxidative stress-mediated injury.
In ATS ﬁbroblasts a non-canonical TGFβ signalling
is activated that exhibits cross-talk with the αvβ3
integrin transduction pathway
To better deﬁne the involvement of TGFβ signalling in ATS aeti-
ology, we used WB to analyse the expression of plasma mem-
brane-bound TGFBRI and TGFBRII receptor subunits as well the
total CTGF, which is a downstream modulator of the TGFβ path-
way. ATS ﬁbroblasts showed markedly lower levels of TGFBRI
compared with the control cells, which was particularly evident
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in patient 3 (P3), wherein the protein was undetectable (Fig. 5A).
In contrast, in the ATS cells, TGFBRII was expressed at higher
levels than in the control ﬁbroblasts. These data indicate that
GLUT10 deﬁciency leads to differential regulation of TGFBRI
and TGFBRII. Despite this clear dysregulation of the canonical
TGFβ receptor subunit organization, the ATS ﬁbroblasts synthe-
sized higher levels of CTGF than the control cells (Fig. 5A),
which conﬁrmed activation of paradoxical TGFβ signalling (15).
Next, we used IF to analyse distribution of the cell membrane-as-
sociated CTGF, which was only organized as elongated patches
in ATS cells (Fig. 5B). Given the known co-distribution and inter-
action between CTGF and αv-dependent integrins (35), such
as αvβ3 and αvβ8, we used IF to analyse the organization of the
αvβ3 integrin and β8 integrin subunit. As shown in Figure 6A,
αvβ3was almost undetectable in the control ﬁbroblasts, whereas,
in ATS cells, it was organized in linear patches on the cell surface
with a pattern resembling the CTGFdistribution (Fig. 5B). Further-
more, we observedmuch lower expression of the β8 integrin sub-
unit in the ATS ﬁbroblasts compared with the control cells
(Fig. 6A), which is consistent with the lower ITGB8 gene expres-
sion observed using microarray (Table 1). We investigated αvβ3
integrin activation through IF by analysing phosphorylation of
Tyr 773 in the β3 integrin subunit (pY773β3 integrin). In the ATS
cells, but not the controls, the phosphorylated β3 integrin subunit
was abundantly organized with a pattern similar to that of αvβ3
(Fig. 6A) and CTGF (Fig. 5B).
To identify the signalling proteins that interact with the acti-
vated αvβ3 integrin in ATS ﬁbroblasts, p125FAK and p60Src were
investigated using IF and WB. As shown in Figure 6A, p125FAK
was abundantly organized in the control and ATS cells, but it
Figure 3. Expression and organization of ALDH1A1 and PPARγ and evaluation of ALDH activity in the control and ATS ﬁbroblasts. (A) IF of ALDH1A1, PPARγ and phospho-
serine 112 PPARγ (pS112-PPARγ) in the control and ATS ﬁbroblasts. Scale bar: 10.8 µm. The experiments were repeated three times. The images are representative of two
control (C1 and C2) and the three ATS cell strains (P1, P2 and P3). (B) WB of ALDH1A1, PPARγ and pS112-PPARγ in two controls (C1 and C2) and in three ATS ﬁbroblasts (P1, P2
and P3). ALDH1A1 and pS112-PPARγ are shown as a 56 and 58 kDa band, respectively, whereas the anti-PPARγmAb that recognizes the two PPARγ isoforms identiﬁed a 53
and 57 kDa band corresponding to PPARγ1 and PPARγ2, respectively. Loading control: β-actin. (C) FACScan analysis of ALDHs activity in the two control and three ATS
ﬁbroblasts; the Bodipy-conjugated aminoacetate developed in BAAA-treated versus untreated cells was used for the measurements. The results are expressed as a
relative quantiﬁcation (RQ) of ALDHs activity in ATS versus the controls; the experiments were repeated three times. Statistical analyses were performed using the
GraphPad Prism software (***P < 0.0001).
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only co-localized with the β3 integrin subunit in ATS ﬁbroblasts,
as demonstrated by the Duolink analysis. Co-localization of the
αvβ3 integrin with p125FAKwas conﬁrmed byWB of the β3 integ-
rin subunit immunoprecipitates that were immunoreacted with
the anti-p125FAK Ab (Fig. 6B). This analysis showed higher levels
of the β3 integrin subunit that co-precipitated with higher levels
of p125FAK in ATS cells compared with controls.
As shown in Figure 6C, both the controls and ATS ﬁbroblasts
abundantly expressed p60Src, which was in its active and
transducing form, as demonstrated by the phosphorylation at
Tyr 416 (pY416-p60Src) and the concomitant non-phosphoryl-
ation at Tyr 527 (npY527-p60Src). Because, in ATS cells, the β3 in-
tegrin subunit immunoprecipitates showed high levels of p60Src
or CTGF (Fig. 6B), the αvβ3 integrin-CTGF complex should trans-
duce to p125FAK and p60Src in the GLUT10-deﬁcient ﬁbroblasts.
To verify a possible correlation between the αvβ3 integrin-
mediated signal transduction and the dysregulated expression
of TGFBRI and TGFBRII observed in the ATS ﬁbroblasts,
Figure 4. Evaluation of the ROS activity and LPO process in the control and ATS ﬁbroblasts. The intracellular ROS activity was evaluated, wherein the control and ATS
ﬁbroblasts were exposed to the non-ﬂuorescent cell-permeable CellROX® reduced reagent, and its conversion was detected in a ﬂuorescent molecule upon oxidation
by ROS. To analyse the LPO process, the control and ATS ﬁbroblasts were grown for 48 h in complete MEM and treated (+LAA) or not (−LAA) with 50 µ LAA, and the
LPO-derived adducts were detected by ﬂuorescence microscopy, wherein the cells reacted with the Click-iT® reaction cocktail containing the Alexa Fluor 488 azide.
Scale bar: 6 µm. The experiments were repeated three times. The images are representative of the two control (C1 and C2) and three ATS cell strains (P1, P2 and P3).
Figure 5.TGFBRI, TGFBRII andCTGFexpression inATS ﬁbroblasts. (A)WBof 50 µg cellmembrane-boundproteins extracted fromcontrol (C1 andC2) andATS (P1, P2 andP3)
ﬁbroblasts immunoreacted with the anti-human TGFBRI and TGFBRII Abs, detecting a 52 and 70 kDa band, respectively. To analyse the expression of CTGF, which was
indicated through a 37 kDa band, the total extract from both cell types was used. Loading control: β-actin. (B) To detect the distribution of the membrane-associated
insoluble fraction of CTGF, the control and ATS ﬁbroblasts were ﬁxed and immunoreacted as previously described (34). Scale bar: 4 µm. The experiments were
repeated three times. A representative image of two control (C1 and C2) and the three ATS ﬁbroblasts (P1, P2 and P3) is shown.
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Figure 6. Activation of αvβ3 integrin signalling that cross-talks with TGFBRII in ATS ﬁbroblasts. (A) IF of αvβ3 integrin, pY773β3, β8 integrin subunit and p125FAK in the
control and ATS ﬁbroblasts. The co-localization of the β3 integrin subunit with p125FAK was evaluated using the Duolink in situ PLA probe kit. Scale bar: 4.5 µm. The
experiments were repeated three times. The images are representative of two control (C1 and C2) and the three ATS cell strains (P1, P2 and P3). (B) WB of the β3
integrin subunit immunoprecipitated from the control (C1 and C2) and ATS (P1, P2 and P3) ﬁbroblasts, which were immunoreacted with the anti-β3 integrin subunit
mAb, anti-p125FAK, anti-CTGF, anti-p60Src, anti-TGFBRII and anti-TGFBRI Abs to detect bands at 95, 125, 37, 60, 70 and 52 kDa, respectively. Loading control: IgG.
(C) IF of p60Src and p38 MAPK in the control and ATS ﬁbroblasts. p60Src activation was monitored using two Abs that recognize the phospho-Tyr416 (pY416-p60Src)
and non-phospho-Tyr527 (npY527-p60Src) residues of the protein; detection of both signals indicates the active form of p60Src. p38 MAPK activation was analysed
using an Ab that recognizes the phospho-Threo180 and Tyr182 (pT180/Y182-p38). Scale bar: 8.3 µm for p60Src and 4.5 µm for p38. The experiments were repeated three
times. The images are representative of two control (C1 and C2) and the three ATS cell strains (P1, P2 and P3). (D) WB of the cell membrane-bound TGFBRII
immunoprecipitated from the control and ATS ﬁbroblasts and immunoreacted with the anti-TGFBRII, anti-TGFBRI and anti-pT180/Y182-p38 MAPK Abs as well as with
the anti-β3 integrin subunit, anti-phospho-Tyr PY20 and anti-p38 MAPK mAbs to detect bands at 70, 52, 38, 95, 70 and 38 kDa, respectively.
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co-immunoprecipitation of these receptor subunits with β3 in-
tegrin was investigated using WB. In the control cells, the poorly
expressed β3 integrin subunit did not co-immunoprecipitate at
detectable levels with either TGFBRII or TGFBRI (Fig. 6B), whereas
the β3 integrin subunit co-immunoprecipitated with high levels
of TGFBRII, but not TGFBRI, in ATS cells (Fig. 6B). These results
were conﬁrmed through immunoprecipitation of TGFBRII and
analysis of the complexes using the anti-TGFBRI and anti-β3
monoclonal antibodies (mAbs). As shown in Figure 6D, high
and comparable levels of TGFBRII were recovered in the control
and ATS extracts. In the control cells, TGFBRII immunoprecipi-
tated with high levels of TGFBRI, whereas, in the ATS cells,
TGFBRII co-immunoprecipitated with signiﬁcant levels of the β3
integrin subunit without TGFBRI (Fig. 6D). Together, these data
suggest an activated cross-talk between αvβ3 integrin-CTGF and
TGFBRII, but not TGFBRI, in ATS cells, which likely involves
p125FAK and p60Src.
To investigate TGFBRII phosphorylation, the global tyrosine
phosphorylation pattern on the TGFBRII immunoprecipitates
was analysed using the PY20 mAb, which recognizes all of the
phosphorylated tyrosine residues (Fig. 6D). Among the numerous
bands in the control and ATS complexes, we detected a 70 kDa
band, which should include the TGFBRII and indicates that the
receptor is in the active form in both cell types. This result with
the presence of p60Src in the immunocomplexes containing
the β3 integrin subunit and TGFBRII, but not TGFBRI, suggests a
role for p60Src in tyrosine phosphorylation of TGFBRII and in ac-
tivation of non-canonical TGFβ signalling involving the CTGF-
αvβ3 integrin transduction pathway.
To deﬁne whether canonical downstream signalling transdu-
cers of the TGFβ pathway are recruited in ATS ﬁbroblasts, we ana-
lysed the expression, distribution and phosphorylation of SMAD2
using IF and either an anti-SMAD2mAb that detects the total pro-
tein or a speciﬁc anti-phospho-SMAD2 Ab that only recognizes
the phosphorylated 465/467 serine residues in active SMAD2
(pSMAD2). In the control and ATS cells, SMAD2 was present ei-
ther in the cytoplasm or nucleus, and SMAD2 was detected at
much lower levels in ATS ﬁbroblasts (Supplementary Material,
Fig. S5). pSMAD2 was detected in control cell nuclei and, at low
levels, in ATS cell nuclei. IF also showed increased levels of
total and phosphorylated p38 MAPK in GLUT10-deﬁcient cells
compared with the controls (Fig. 6C). As shown in Figure 6D,
the TGFBRII recovered from the ATS cell extracts immunopre-
cipitated with increased levels of p38 MAPK compared with the
controls, which was in the active form, as demonstrated by
the phosphorylation at Threo180 or Tyr182 (pT180/Y182-p38).
In conclusion, these data suggest that, in ATS cells, TGFβ signal-
ling should be activated by an SMAD2-independent TGFBRII-
mediated non-canonical pathway that exhibits cross-talk with
αvβ3 integrin signalling, which involves CTGF, p125FAK, p60Src
and p38 MAPK. This MAPK seems to play a pivotal role in ATS ae-
tiopathogenesis because it might also be activated by stimuli
other than TGFβ signalling, including an imbalance of redox
homeostasis due to ROS-induced LPO-derived aldehydes.
Stable expression of GLUT10 in ATS ﬁbroblasts
normalizes ALDH1A1 and PPARγ activity, ROS
production and the LPO process, rescues canonical
αvβ3-independent TGFβ signalling and partially
restores the ECM
To demonstrate that the alteration of gene expression, protein
synthesis and organization observed in the ATS ﬁbroblasts are
downstream effects of the SLC2A10 loss-of-function mutations,
we generated a stable GLUT10 expression vector (pG10), which
was transfected into the ATS patient 1 (P1) cells, and analysed a
selection of dysregulated genes/proteins by qPCR, IF and WB.
As shown in Figure 7A, pG10-transfected ﬁbroblasts stably ex-
pressed and abundantly organized GLUT10 similarly to control ﬁ-
broblasts (Fig. 1). We used qPCR analyses for a small selection of
upregulated genes, i.e. ALDH1A1 and PPARG, or downregulated
genes, i.e. LOXL4, TNXB and DCN, in the ATS versus the control
cells to compare the mRNA levels of the pG10 versus the empty
vector (mock)-transfected ATS P1 cells. In particular, the
ALDH1A1 and PPARG mRNA levels showed an approximately 2-
fold decrease in the pG10 versus mock cells, and LOXL4 and
TNXB were upregulated ∼2.5-fold after transfection (Supplemen-
tary Material, Fig. S6A).
In the transfected ATS ﬁbroblasts, IF and WB showed that
GLUT10 expression signiﬁcantly decreased the pS112-PPARγ le-
vels (Fig. 7A and Supplementary Material, Fig. S6B), which were
undetectable in the nuclei (Fig. 7A), in association with normal-
ized intracellular ROS production, LPO levels (Fig. 7A) and
ALDH1A1 synthesis and activity (Fig. 7A and Supplementary
Material, Fig. S6B,C). Overall, these data demonstrate that
GLUT10 plays a key role in maintaining redox homeostasis and
corroborates the hypothesis that a PPARγ-dependentmechanism
contributes to ROS overproduction and is associated with ATS
aetiopathogenesis.
For TGFβ signalling, TGFBRI, which was undetected by IF in
the mock-transfected cells, was upregulated and organized
in the plasma membrane in the GLUT10-expressing ATS cells
(Fig. 7B-a). Consistent with this result, for these transfected
cells, WB showed higher levels of the TGFBRI isoforms compared
with the untransfected and mock-transfected cells (Supplemen-
tary Material, Fig. S6B). Furthermore, we only detected SMAD2,
total and phosphorylated, in the cytoplasm and nucleus of
pG10-transfected cells (Fig. 7B-a). These data suggest that
GLUT10 expression rescues canonical TGFβ signalling in ATS
cells. To corroborate theseﬁndings, TGFBRIIwas immunoprecipi-
tated from the control andmock- and pG10-transfected ﬁbroblast
extracts, and the immunocomplexes were analysed for the pres-
ence of the TGFBRI isoforms and β3 integrin subunit. As reported
in Figure 7B-b, similar levels of TGFBRII were recovered from
the control and both transfected ATS ﬁbroblast cell types. In
the control cells and in ATS ﬁbroblasts expressing GLUT10,
TGFBRII immunoprecipitated higher levels of TGFBRI than in
mock-transfected counterparts. The β3 integrin subunit was
recovered in abundance by TGFBRII in the mock-transfected
cells, but was almost undetected in the GLUT10-expressing
counterpart cells. These results are supported by IF, which
showed that the GLUT10 expression was associated with αvβ3
integrin disorganization and β8 integrin subunit re-organization
(Fig. 7C). Furthermore,we examined the co-immunoprecipitation
of both the p60Src and p38MAPK active formswith TGFBRII using
the anti-pY416-p60Src and anti-pT180/pY182-p38 Abs, respectively.
The two phosphorylated proteins were abundantly recovered in
the immunocomplexes from the mock-transfected ATS cells
but were recovered at signiﬁcantly lower levels in the GLUT10-
expressing ﬁbroblast and control cell immunoprecipitates
(Fig. 7B-b), which is consistent with lower levels of p38 MAPK in
pG10-transfected ﬁbroblasts.
To conﬁrm that the p38MAPKphosphorylationwas due to the
presence of the active form of p60Src, the control, untransfected
and mock- and pG10-transfected ATS ﬁbroblasts were treated
with subapoptotic concentrations of the p60Src inhibitor PP2
and its inactive analogue PP3. TGFBRII was then immunoprecipi-
tated and tested for binding to p38 and its phosphorylated form.
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As shown in Figure 7B-c, the PP3 treatment did not affect p38
phosphorylation in the untransfected and mock-transfected
ATS cells, whereas the PP2 treatment completely removed phos-
phorylation in these cells, even though the total protein levels
weremaintained. This result suggests that, in ATS cells, p38 phos-
phorylation is due to non-canonical TGFβ signalling and occurs
downstream of the p60Src kinase activity, which should be in-
volved in phosphorylating TGFBRII. Together, these data conﬁrm
Figure 7. Phenotypic rescue of ATS ﬁbroblasts after stable GLUT10 expression. (A) IF of GLUT10, pS112-PPARγ and ALDH1A1 in mock- and pG10-transfected ATS P1
ﬁbroblasts using the anti-human GLUT10, anti-pS112-PPARγ Ab and anti-ALDH1A1 mAb. Intracellular ROS and LPO were evaluated using the CellROX® Green assay
and the Click-iT® LAA kit, respectively. Scale bar: 5 µm. The experiments were repeated three times. Representative images are shown. (B-a) IF of TGFBRI, SMAD2 and
its phosphorylation (pSMAD2) in mock- and pG10-transfected ATS P1 ﬁbroblasts using the anti-TGFBRI and anti-phospho-SMAD2 Abs as well as the anti-SMAD2
mAb. Scale bar: 4 µm for TGFBRI, 8.3 µm for SMAD2 and pSMAD2. The experiments were repeated three times. Representative images are shown. (B-b) WB of the cell
membrane-bound TGFBRII immunoprecipitated from the control (C1), mock- and pG10-transfected P1 ﬁbroblasts, which were immunoreacted with the anti-TGFBRII,
anti-TGFBRI, anti- pT180/Y182-p38 MAPK and anti-pY416-p60Src Abs to detect bands at 70, 52, 38 and 60 kDa, respectively, as well as with the anti-β3 integrin subunit
and anti-p38 MAPK mAbs to detect bands at 95 and 38 kDa, respectively. (B-c) The involvement of p60Src in p38 MAPK phosphorylation was investigated through
treating the untransfected control (C1) and ATS (P1) ﬁbroblasts as well as the mock- and pG10-transfected ATS cells with 50 µ of PP2 and PP3. The TGFBRII
immunoprecipitates were reacted with the anti-TGFBRII and anti-pT180/Y182-p38 Abs as well as the anti-p38 MAPK mAb. (C) IF of the αvβ3 integrin, β8 integrin subunit,
DCN, FBNs and ELN inmock- and pG10-transfectedATS P1 ﬁbroblasts. The cells were grown for 48 h before immunodetectionwith the anti-αvβ3, β8 andDCNmAbs and for
15 days before reacting with the anti-FBN and anti-ELN mAbs. Scale bar: 3.5 µm for αvβ3 integrin, β8 integrin subunit and DCN; 7 µm for FBN and ELN. The experiments
were repeated three times. Representative images are shown.
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that loss of GLUT10 expression affects canonical TGFβ signalling
and recruits an alternative pathway that involves TGFBRII cross-
talk with the αvβ3 integrin through p60Src activation, which is
involved in TGFBRII phosphorylation, activating p38 MAPK. Sup-
porting this novel disease-associated pathway, ATS ﬁbroblasts ex-
pressing GLUT10 rescue canonical TGFBRI/TGFBRII signalling,
which is αvβ3 integrin, p60Src and p38 independent.
Finally, to verify whether the recovery of normal redox
homeostasis and canonical TGFβ signalling is associated with ﬁ-
brillar ECM organization in ATS ﬁbroblasts, the pG10-transfected
cells were analysed using IF for COLLIII-, COLLV-, DCN-, FBN- and
ELN-ECM organization (Fig. 7C). COLLIII and COLLV organization
in the ECMwasnot rescued byGLUT10 expression at up to 15 days
of culture (data not shown). However, DCN, which was absent in
the untransfected (Fig. 1) and mock-transfected ATS ﬁbroblasts,
was abundantly organized in GLUT10-expressing cells grown
for 48 h (Fig. 7C), even without modulated gene expression
(Supplementary Material, Fig. S6A). At this period during culture,
the FBNs- and ELN-ECMs were not organized, but 15 days
after seeding, the GLUT10-expressing ﬁbroblasts secreted and
organized thin ﬁbrils of FBNs and ELN (Fig. 7C). These data are
consistent with the upregulated LOXL4 expression observed
using qPCR in the GLUT10-expressing ATS cells (Supplementary
Material, Fig. S6A) and with restored canonical TGFβ signalling.
These data suggest that GLUT10 rescue is associated with organ-
ization of several ECM components and yields control-like ECM
homeostasis.
Discussion
Although SLC2A10 was identiﬁed as causal gene for ATS in 2006
(3), the speciﬁc role of GLUT10 remains largely unknownand con-
troversial. Different hypotheses, i.e. glucose and/or DAA trans-
port into different intracellular compartments (3,10,17,18), have
been drawn, but neither the exact localization nor the trans-
ported substances have been clariﬁed with certainty. Further-
more, the interaction between GLUT10 and the TGFβ pathway
(3,14) was not elucidated.
Transcriptome analysis conﬁrmed the crucial role of GLUT10
in ATS, wherein GLUT10 maintains ECM homeostasis because
several ECM-related genes involved in focal adhesion, ECM-
receptor interaction and TGFβ signalling were dysregulated.
Interestingly, the array results also suggested oxidative stress in
ATS ﬁbroblasts, which was validated by increased intracellular
levels of ROS- and LPO-derived adducts. Speciﬁcally, we observed
signiﬁcant upregulation of several genes associated either with
maintaining redox homeostasis, including the cellular response
to ROS- and LPO-derived aldehyde detoxiﬁcation mechanisms
or cell energy balance, i.e. polyunsaturated fatty acid (PUFA) me-
tabolism. The LPO process is initiated by interactions between
ROS and PUFAs, such as linoleic, γ-linolenic, or arachidonic
acids, which trigger chain peroxidation (36). Because LPOwas de-
tected in ATS ﬁbroblasts evenwithout the speciﬁc LAA substrate,
the increased lipid metabolism observed in ATS cells may have
sustained this process. The resulting lipid radicals interact with
oxygen, which propagates the reaction via peroxyl radical inter-
mediates and generates lipid hydroperoxides and aldehydes,
such as 4-hydroxy-2-nonenal (4-HNE), which is considered a
major bioactive marker of LPO (37). LPO can be terminated by
so-called chain-breaking antioxidants, such as vitamin E.
Notably, AA protects against this deleterious process either by
acting as an ROS scavenger or by the one-electron reduction of
lipid hydroperoxyl radicals via the vitamin E redox cycle (19).
LPO-derived aldehydes are increasingly recognized as markers
of cellular dysfunction and degeneration in a range of disorders
including cardiovascular diseases (38). They interact with lipids,
nucleic acids and proteins, which impairs their function (39).
Failure to eliminate protein adducts results in proteasome inhib-
ition, altered protein turnover and stress response pathway
activation, such as MAPKs and ER stress induction, which com-
promises the ER redox balance and, ultimately, leads to cell
death (40). The main LPO-derived aldehyde detoxiﬁcation me-
chanisms include GSH, glutathione-S-transferases, aldo-keto re-
ductases and ALDHs, including ALDH1A1, which is upregulated
in ATS ﬁbroblasts. This enzyme converts aldehydes to carboxylic
acids, contributes to the antioxidant arsenal because the NAD(P)
H produced during this reaction is used to regenerate GSH and
acts as direct antioxidant for ROS (41). The increased ALDH1A1
activity can be considered a compensatory mechanism to rescue
ATS cells from oxidative stress triggered by increased ROS-
induced LPO.
Oxidative stress triggers a series of responses,which results in
altered PPARs expression and activity. Redox statesmay regulate
PPARs signalling via transcription regulation and PTMs (42). PPAR
expression and activity have been observed in endothelial cells
(43) and AVSMCs (44), which suggests that PPARs are redox-
sensitive transcription factors in the vasculature and are select-
ively activated by oxidized fatty acids. Peroxidized PUFAs
promote PPARγ-mediated transcription and PPARγ binding to
speciﬁc target genes, including the PPARG itself (45). PPARγ also
regulates lipid and glucidic metabolism (27); therefore, in ATS
cells, the increased PPARγ may be involved in upregulating
genes related to peroxisomal β-oxidation and PUFA metabolism,
as shown in the array. Overall, PPAR expression and activity may
be altered by the cellular energy metabolism status, and oxida-
tive stress is attributed to altered PPAR expression and activity
as adaptive or maladaptive feedback (42). In ATS cells, increased
PPARG expression, enhanced protein synthesis, and preferential
distribution of phosphorylated (Ser112) PPARγ at the nuclear level
with the evidence of ROS-induced oxidative stress sustained
by enhanced lipid, suggest aberrant PPARγ activity. Such aberrant
activity may ﬁnally produce a vicious cycle that sustains
oxidative stress. This hypothesis is supported by the preliminary
results of PPARγ inhibition. In control cells, the speciﬁc antagon-
ist enhanced ROS synthesis, which is consistent with a pivotal
antioxidant role for PPARγ, which, under physiological condi-
tions and via transcriptional regulation, activates scavenger
genes (42). In ATS ﬁbroblasts, PPARγ inhibition attenuated oxida-
tive stress, which indicates that, despite its positive beneﬁts to
other cells/tissues, PPARγ activation is detrimental under oxida-
tive stress-induced injury. Formal proof that GLUT10 deﬁciency
causes oxidative stress due to enhanced ROS-induced LPO likely
sustained by increased lipid metabolism through a PPARγ-
mediated mechanism was generated by stable GLUT10 expres-
sion in ATS ﬁbroblasts, which normalized redox homeostasis
and ALDH1A1 synthesis. One study recently reported that ROS-
induced PPARγ alterations, which are associated with PPARγ
Ser112 phosphorylation, enhance oxidative stress-mediated
renal tubular cell damage (46). Therefore, we supposed that, in
ATS cells, modulated PPARγ activity involves Ser112 phosphoryl-
ation. Given that this PTM can produce different transcription
outcomes depending on the physiological context and kinases
involved (33), in ATS cells, the speciﬁc protein kinase(s) should
be identiﬁed in future studies.
ROS involvement in the ATS aetiology is intriguing because
ROS are involved in different vascular-related pathological condi-
tions, i.e. atherosclerosis, hypertension, stroke, cardiomyopathies,
cardiac hypertrophy and cardiac congestive insufﬁciency (47,48).
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ROS can affect ECM organization through protein fragmenta-
tion, which is also mediated by proteolytic enzymes, and sugar
structure variation. Recently, oxidized ELN fragments were iden-
tiﬁed as associated with arterial diseases (49); in AVSMC, ROS in-
duce ECM degradation during vascular ECM remodelling in
aneurysms (50); and ROS can damage ECM proteoglycan glycosa-
minoglycan chains (51). However, ECM disassembly can promote
ROS production and induce the LPO process (52). Loss of matrix
contacts decreases cell uptake of nutrients, such as glucose and
glutamine, which exacerbates fuel deprivation for the citric acid
cycle and leads to anATP shortage.Moreover, diminished activity
of the pentose phosphate pathway leads to a critical shortage of
NADPH, which is an ROS-reducing/scavenging agent. To com-
pensate for the low levels of ATP and NADPH, peroxisomal fatty
acid degradation is turned on with a concomitant release of add-
itional ROS (52). Furthermore, in regulating intracellular homeo-
stasis, a complex interaction between different subcellular
compartments occurs. ROS can be generated in mitochondria
as a respiration by-product and in ER as a by-product of protein
synthesis, PTMs, oxidative protein folding, trafﬁcking and detoxi-
ﬁcation, which require redox constituents, carbohydrate precur-
sors and lipids for disulphide bond and glycoprotein formation.
ROS can perturb ER protein folding as well as induce ER stress,
and oxidants, such as peroxides and LPO-derived aldehydes,
may activate the unfolded protein response (53,54). In addition
to ROS overproduction, in ATS patient ﬁbroblasts, disorganized
ELN-, COLLIII-, COLLV-, FBNs- and DCN-ECM were observed con-
comitant with cytoplasmic retention of certain such proteins,
such as ELN, COLLIII and COLLV. Generating high levels of LPO-
mediated adducts in ATS ﬁbroblasts may affect the amino acid
structure of ELN and COLLs and negatively inﬂuence their secre-
tion and organization in the ECM. The intracellular protein reten-
tion may lead to defective trafﬁcking and ultimately generate ER
stress. Furthermore, the reduced LOXL4 expression that was ob-
served in ATS cells using the array might affect COLL and ELN
strength and elasticity and may be involved in generating mis-
folded or unfolded proteins, which might ultimately increase
ROS production. Similarly, expression of the TGM2 transglutami-
nase involved in PTMs and organization of several ECM proteins
was also downregulated in ATS cells, which is consistentwith the
FN and DCN disorganization observed in these cells (1,3, this
work). Thus, although not investigated in this study, ER stress
in ATS ﬁbroblasts cannot be excluded.Moreover, based on the co-
factor enzyme model of ATS aetiology, the defective synthesis
and assembly of COLLs and ELN in ATS cell ECM may be due to
impaired DAA uptake in the ER (10,17).
TGFβ is an important determinant of matrix deposition, ves-
sel structure and neointima formation. This growth factor is se-
creted in a large latent complex (LLC) that consists of TGFβ, an
inhibitor, i.e. latency-associated protein (LAP), and one of the la-
tent TGFβ-binding proteins (LTBPs). LTBPs are covalently cross-
linked to ECM proteins such as FBNs, DCN, FN, TN-X and COMP
by transglutaminases and thus localize latent TGFβ in the ECM.
The TGFβ activation process involves LLC release from the ECM
followed by LAP proteolysis to release active TGFβ to its recep-
tors. Alternatively, upon mechanical stretch, integrins, such as
αvβ3 and αvβ8, activate TGFβ by binding the RGD motif in LAP
and inducing TGFβ release from its latent complex (55). De-
creased expression of DCN and disarray of DCN- and FBNs-
ECMs was demonstrated in ATS ﬁbroblasts, which suggests
higher TGFβ bioavailability, which is consistent with the upre-
gulated TGFβ signalling indicated by enhanced CTGF expression
(3, this study). Furthermore, because ROS can activate latent
TGFβ1 (56), oxidative stress in ATS cells likely contributes to
this process. Dysregulated TGFβ signalling associated with ar-
terial aneurysm formation is common in several conditions
that are referred to as TGFβ vasculopathies such as Marfan syn-
drome and Loeys-Dietz syndrome, which involve the constitu-
tive stimulation of canonical and paradoxical signalling,
respectively (16).The canonical TGFβ pathway requires ligand
binding to a heteromeric complex composed of TGFBRI and
TGFBRII serine/threonine kinase receptors. The TGFBRI receptor
directly phosphorylates SMAD2/3, which then binds SMAD4, al-
lowing it to accumulate in the nucleus, where the complex tran-
scriptionally activates many target genes. TGFβ also activates
non-SMAD-signalling pathways, such as the p38 and JNK
MAPK pathway (57).
To discern the molecular interactors involved in TGFβ signal-
ling activated in ATS cells, TGFBRI, TGFBRII and CTGF expression
was investigated. The high level of TGFBRII at the ATS cell mem-
brane is not consistent with TGFBRI but is associated with upre-
gulated CTGF and αvβ3 integrin, which co-immunoprecipitate
with TGFBRII and are abundantly and similarly organized at the
cell membrane. αvβ3 integrin is not organized by control cells,
which, in turn, express the β8-dependent integrins that are almost
absent in ATS ﬁbroblasts. A cell survival role for αvβ3 integrin was
reported in Ehlers-Danlos syndrome skin ﬁbroblasts, wherein this
receptor rescues the cells from apoptosis induced by ECM disas-
sembly due to COL5A1 and COL3A1mutations (58,59).
In ATS cells, the β3 integrin subunit is phosphorylated at tyro-
sine 773 and co-immunoprecipitates with p125FAK and phos-
phorylated p60Src, which suggests activation of canonical αvβ3
integrin-mediated signal transduction. Moreover, in ATS cells,
this integrin co-immunoprecipitates with TGFBRII but not with
TGFBRI, which is downregulated. p125FAK recruitment by the
β3 integrin subunit is consistent with its reported role as a key
mediator of TGFβ signalling (60,61). Together, these data suggest
that GLUT10 loss leads to non-canonical αvβ3 integrin-TGFBRII
cross-talk.
A dual role for αvβ3 integrin has been reported, which support
its cross-talk with TGFBRII. The ﬁrst role is in binding to CTGF,
which was reported in endothelial cells, where it stimulates
angiogenesis and ﬁbrotic mechanisms (62). CTGF-αvβ3 integrin
complex signalling through p60Src activation and downstream
ERK pathway modulation have been reported (35). Second, the
LLC complex binds αv-dependent integrins, including αvβ3, be-
cause LAP contains an RGD domain by which TGFβ may be acti-
vated (55,63). TGFβ activation induces αvβ3 integrin association
with TGFBRII, which initiates cross-talk (55,64,65) and leads to
p60Src-mediated tyrosine 284 (Y284) phosphorylation of TGFBRII
that, in turn, activates p38 MAPK, which is involved in several
functions, such as adhesion, migration and ECM remodelling
(66,67). ATS ﬁbroblasts exhibit a similar transduction pathway
based on the following. The ATS cells’ TGFBRII co-immunopreci-
pitateswith the β3 integrin subunit, which is tyrosine phosphory-
lated as well as in the control ﬁbroblasts; however, only in the
GLUT10-deﬁcient cells, TGFBRII co-immunoprecipitates phos-
phorylated p60Src and p38 MAPK. PP2-mediated inhibition of
p60Src leads to complete elimination of p38 MAPK phosphoryl-
ation within TGFβ signalling in the ATS ﬁbroblasts. These data
support a p60Src-dependent TGFBRII-mediated activation of
p38 MAPK. Furthermore, stable GLUT10 expression in ATS cells
abolishes the cross-talk between TGFBRII and αvβ3 and rescues
the SMAD2-dependent TGFBRI/TGFBRII canonical pathway,
which is associated with partial re-organization of the ECM.
These results clearly demonstrate that GLUT10 is involved in
maintaining the canonical TGFβ pathway. For p38-mediated
TGFβ signalling, currently, we cannot characterize the speciﬁc
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TGFBRII tyrosine residues phosphorylated by p60Src (68), due to a
lack of speciﬁc Abs.
p38 MAPK is a stress-activated protein and a key enzyme for
survival, inﬂammation and regulation of ER homeostasis. LPO
and, particularly, 4-HNE, activate ERK, JNK and p38 MAPK as
negative regulators of cellular stress and confer cytoprotection
against LPO-mediated cell injury (69). Because ATS cells show
an increase in the LPO process, the derived toxic aldehydes
might also be involved in p38MAPK activation,which is indicated
by the increased levels of total and phosphorylated p38. Interest-
ingly, an oxidative stress imbalance is associated with aberrant
elastogenic activity, which is regulated by TGFβ signalling. Re-
cently, impairment of the TGFβ pathway by oxidative exposure
of human skin ﬁbroblasts has been reported (70), and inhibition
of TGFβ signalling by 4-HNE, which triggers ELN assembly in
the ECM, was reported in oxidative stress-associated aging
using human skin ﬁbroblasts (71). Moreover, CTGF production
by TGFβ-activated p38MAPK signalling independent of SMAD ac-
tion was reported (72,73).
In summary, our approach demonstrates that GLUT10
deﬁciency alters redox/energetic homeostasis, which leads to
oxidative stress and is likely to be sustained by altered lipid
metabolism and PPARγ maladaptive feedback that contribute to
the enhanced ROS-induced LPO process, which, in turn, elicits
ALDH1A1 antioxidant activity. Furthermore, our data show that
GLUT10 is crucial for both TGFβ signalling and ECM homeostasis
because, in ATS ﬁbroblasts, non-canonical αvβ3 integrin-TGFBRII
cross-talk is activated, which is ineffective at supporting physio-
logical ECM organization. Our ﬁndings support both “antioxi-
dant-” and “enzyme cofactor-” models of a vitamin C-related
pathology, but a new hypothesis of ATS aetiology can also be en-
visaged. In particular, since the GLUT10 re-expressing ﬁbroblasts
rescue the redox homeostasis, canonical TGFβ signalling and
ECM organization under low non-physiological AA concentra-
tions (74), a transport-independent function for GLUT10 cannot
be excluded. Several transporters or channels are known to pos-
sess multiple functions (75), for instance the glucose-6-phos-
phate transporter in the ER was recently shown to be a key
regulator of autophagy in a transport-independent manner (76).
Further studies are necessary to verify the existence of such a
function for GLUT10.
In conclusion, our data add new insights into the ATS dysre-
gulated biological pathways and deﬁnition of the pathomechan-
isms involved in this disorder and may provide a basis for
identifying potential therapeutic options.
Materials and Methods
Patients and ethics statement
Skin ﬁbroblasts cultures from three ATS patients and three unre-
lated age-matched healthy donors were established in our lab
from skin biopsies by standard protocols. All of the three ATS pa-
tients were previously characterized for three different muta-
tions in the SLC2A10 gene (3,4,7). In particular, ATS patient 1
(P1) was homozygous for the c.1334del microdeletion (p.Gly445-
Glufs*40) that leads to the activation of the nonsense-mediated
mRNA decay (3); patient 2 (P2) was homozygous for the c.1411
+1G>A splice donormutation, which causes in frame exon 3 skip-
ping (p.Val430_Ile470del) (7); patient 3 (P3) was compound het-
erozygous for the c.1309G>A (p.Glu437Lys) and the c.1330C>T
mutations (p.Arg444*) (4). Written informed consent was
obtained from each patient for skin biopsy. This study was ap-
proved by the medical ethical committee of the University
Hospital Spedali Civili of Brescia and was performed in accord-
ance with the Declaration of Helsinki Principles.
Cell cultures and antibodies
Dermal ﬁbroblasts were grown in vitro at 37°C in a 5% CO2 atmos-
phere in Earle’s modiﬁed Eagle’s medium (MEM) supplemented
with 2 m -glutamine, 10% FBS, 100 µg/ml penicillin and strep-
tomycin (Life Technologies, Carlsbad, CA, USA) (complete MEM).
Fibroblasts were analysed at the same in vitro passage number
(from 3rd to 7th).
Polyclonal rabbit Ab against the human GLUT10 was from
Alpha Diagnostic Int. Inc. (San Antonio, TX, USA), the mAb
against β-actin (clone AC-74) and the horseradish peroxidase
(HRP)-conjugated anti-rabbit, anti-goat and anti-mouse second-
ary Abs were from Sigma Chemicals (St. Louis, MO, USA). The
goat anti-COLLV and anti-COLLIII Abs were purchased from Life-
Span BioSciences, Inc. (Seattle, WA, USA). The anti-DCN mAb
(clone 115402) and the goat anti-human TGFBRI/ALK5 Ab were
from R&D Systems, Inc. (Minneapolis, MN, USA). The rabbit
anti-TGFBRI, which recognizes all of the receptor isotypes, the
anti-phospho-Tyr416 p60Src (pY416-p60Src), the anti-non-phos-
pho-Tyr527 p60Src (npY527-p60Src), the anti-phospho-SMAD2
(pSMAD2) (Ser465/467) Abs, the rabbit anti-PPARγ (clone 81B8),
the anti-SMAD2 (clone 86F7) and the rabbit anti-p60Src (clone
36D10) mAbs were purchased from Cell Signalling Technology,
Inc. (Boston, MA, USA); the afﬁnity puriﬁed anti-phospho-S112
PPARγ (pS112-PPARγ) Ab, the rabbit anti-p38 MAPK phospho-
T180/Y182 (pT180/Y182-p38) Ab, the mouse anti-β8 integrin
subunit Ab, and the mouse anti-phospho-tyrosine (PY20) and
anti-p38 MAPK (M138) mAbs were from Abcam (Cambridge,
UK); the anti-FBN (clone 11C1.3) mAb was from NeoMarkers (Fre-
mont, CA); the mouse anti-ELN (clone 10B8), the anti-β3 integrin
(clone B3A) and the anti-αvβ3 (clone LM609) integrin mAbs were
from Millipore-Chemicon Int. (Billerica, MA, USA). The rabbit
anti-human TGFBRII, the anti-human p125FAK, the goat anti-
CTGF afﬁnity puriﬁed Abs, and the mouse anti-ALDH1A1 mAb
(clone B-5) were from Santa Cruz Biotec. Inc. (Heidelberg, Ger-
many). The rabbit anti-integrin β3 pY773phosphospeciﬁc Ab was
from Biosource Int. Inc. (Camarillo, CA, USA) and the rabbit
anti-CTGF was from Thermo Scientiﬁc Pierce (Rockford, IL, USA).
Rhodamine-conjugated anti-goat secondary Ab was obtained
from Calbiochem-Novabiochem INTL, the Alexa Fluor® 488 anti-
rabbit and Alexa Fluor®594 anti-mousewere purchased from Life
Technologies.
Microarray procedures
To screen for candidate genes that may contribute to the patho-
genesis of ATS, we performed a transcriptome-wide expression
proﬁling using the Affymetrix Gene 1.0 ST platform by comparing
the gene expression patterns of skin ﬁbroblasts of the three ATS
patients with those of three healthy individuals. The microarray
analysis was performed starting from 250 ng of total RNA per
sample; labelled targets were prepared using Ambion® Whole
Transcript Expression Kit (Life Technologies) and GeneChip®
WT Terminal Labelling and Controls Kit (Affymetrix) in accord-
ance with manufacturers’ instructions. In brief, total RNA was
primed with synthetic primers containing a T7 promoter se-
quence, reverse transcribed into ﬁrst-strand cDNA and converted
into double-stranded cDNA. Following the in vitro transcription,
10 µg of cRNA was reverse transcribed using random primers.
5.5 µg of second-cycle cDNA was fragmented, biotin labelled
and hybridized for 16 h at 45°C onto the arrays. The chips were
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then washed in the Affymetrix GeneChip Fluidics station FS 450,
scanned using the Affymetrix GeneChip scanner 3000 7G system
and analysed with the GeneChip® Operating Software. Analysis
of the miRNA expression proﬁle was performed on three ATS pa-
tients’ ﬁbroblasts and controls in accordance with the manufac-
turer’s instructions, starting from 250 ng of total RNA labelled
with the Affymetrix Flash Tag Biotin Labelling Kit, followed by
the hybridization on the GeneChip miRNA 3.0 array. The result-
ing CEL ﬁles were analysed using Partek® Genomics Suite soft-
ware version 6.6 (Partek Inc., St. Louis, MO, USA). Analysis of
variance (ANOVA)was used to identify the DEGs betweenATS pa-
tients and controls, using a combination of fold-change value
>1.5 and an uncorrected P-value threshold at 0.05 (P < 0.05). To
identify miRNAs that showed a signiﬁcantly different expression
in ATS cells, one-way ANOVA was performed and the samples
were ﬁltered for fold changes >1.5 with an uncorrected P < 0.05.
To identify signiﬁcantly perturbed biological processes and
enriched pathways in ATS patients, the DAVID database was
queried to grouped DEGs into the functional clusters of GO anno-
tations. The miRNA target prediction databases miRWalk,
TargetScan andmiRDBwere queried to correlate the differentially
expressedmiRNAswith the DEGs. All microarray data areMIAME
compliant, and the raw data have been deposited in the MIAME
compliant GEO database with the accession numbers GSE70683
and GSE71172.
Quantitative real-time PCR
The relative mRNA levels of a series of selected genes/miRNAs
identiﬁed by array analysis were conﬁrmed by qPCR. In particu-
lar, 3 µg of total RNA puriﬁed from skin ﬁbroblasts of three ATS
patients and unrelated healthy controlswere reverse-transcribed
with random primers by standard procedure. qPCR reactions
were performed with SYBR Green qPCR Master Mix (Life Tech-
nologies), 10 ng of cDNA, andwith 10 µMof each primers set. Am-
pliﬁcationswere performed in triplicate using the ABI PRISM 7500
Real-Time PCR System by standard thermal cycling conditions.
The HPRT, GAPDH, ATP5B, CYC1 and RPLP0 reference genes were
also ampliﬁed for normalization of cDNA loading. Relative
mRNA expression levels were normalized to the geometric
mean of these housekeeping genes and analysed using the
2−(ΔΔCt) method. Expression of miRNA was assayed using stem-
loop RT–PCR starting from 50 ng of total RNA in a ﬁnal volume
of 15 µl followed by TaqMan-based qPCR proﬁling in accordance
with the manufacturer’s instructions (Life Technologies). The
qPCR reaction contained 1.3 µl of reverse transcriptase product,
10 µl of TaqMan 2× Universal PCR Master Mix and 1 µl of the ap-
propriate TaqMan MicroRNA assay containing primers and
probes for the target miRNA. The expression of selected miRNA
was based on the 2−(ΔΔCt) method, using RNU66 as internal nor-
malization transcript, and all of the qPCR reactions were run in
triplicate. Ampliﬁcation plots, dissociation curves and threshold
cycle values were generated by ABI Sequence detection System
software version 1.3.1. Statistical analyses were performed
using GraphPad Prism software (San Diego, CA, USA). The results
were expressed as the mean value of relative quantiﬁcation (RQ)
± SEM. Statistical signiﬁcance between groups was determined
using unpaired Student’s t-test, or the one-way ANOVA followed
by Tukey’s post hoc test (*P < 0.05, **P < 0.01 and ***P < 0.001).
Construction of a stable GLUT10 expression vector
The full-length human SLC2A10 cds (refseq: NM_030777.3), from
the Kozak consensus sequence to the stop codon, was ampliﬁed
using the total RNA from normal skin ﬁbroblasts with the Super-
Script III One-Step RT-PCR System. The sequence was inserted
into the eukaryotic pEF6/V5-His-TOPO™ expression vector (con-
taining the blasticidine selectable marker gene and the strong
human elongation factor 1α promoter) using standard proce-
dures (Life Technologies). This expression vector (pG10) and the
empty cloning vector (mock) were stably transfected into skin ﬁ-
broblasts of ATS P1 using the FUGENE 6 liposomal transfection re-
agent in accordancewith themanufacturer’s instruction (Roche).
The cells were selected by adding selective medium (2 µg/ml of
blasticidine) that was changed every 3 days until all sensitive
cells were eliminated. Established cell lines with an integrated
pG10 construct or empty vector were expanded for subsequent
experiments. The total RNA from all untransfected and trans-
fected ﬁbroblasts was extracted using the Qiagen RNeasy kit in
accordance with the manufacturer’s instructions (Qiagen,
Hilden, Germany). RNA quality control was assessed using an
Agilent 2100 BioAnalyzer (Agilent Technologies, Santa Clara,
CA, USA).
Immunoﬂuorescence microscopy
To analyse the GLUT10 distribution, control, untransfected and
transfected ATS ﬁbroblasts were grown for 48 h and reacted for
2 min with 3% paraformaldehyde (PFA)/0.5% Triton X-100,
20 min with 3% PFA, washed with 100 m glycine/PBS, blocked
for 30 min with 5% BSA and immunoreacted ON at +4°C with
20 µg/ml anti-GLUT10 Ab. To analyse the ELN organization, the
cells were grown 7–15 days in complete MEM, ﬁxed in 1% PFA
for 20 min, treated 1 h at 37°Cwith 10 U/ml hyaluronidase diluted
in 5% FBS-MEM, and, after washing, immunoreactedwith 1:50 di-
luted anti-ELN mAb for 1 h. The DCN organization was analysed
48 h after seeding ﬁxing cells with 3% PFA/PBS for 20 min. Subse-
quently, the cells were incubated for 1 h with 25 µg/ml anti-DCN
mAb, which recognized the core protein. The COLLIII, COLLV and
FBN organization into ECM, was monitored for the control, un-
transfected, and transfected ATS ﬁbroblasts from 48 h to 15
days, and the TGFBRI, PPARγ, ALDH1A1 and pSer112-PPARγ distri-
bution was analysed in cells treated or not ON with increasing
quantities, from 1.0 to 2.5 µM, of the PPARγ antagonist
T0070907. The cells were ﬁxed in cold methanol and reacted for
1 h with anti-COLLIII or anti-COLLVAbs; anti-FBN, which recog-
nized all of the FBN isoforms; anti-ALDH1A1 mAbs diluted
1:100 in 1% BSA or 14 µg/ml anti-TGFBRI Ab, 2.5 µg/ml anti-
pS112-PPARγ Ab and 1:200 diluted anti-PPARγ mAb. Before the
anti-pS112-PPARγ Ab incubation, we permeabilized and blocked
the cells with 1% BSA/10% normal goat serum/0.3  glycine in
0.1% PBS-Tween 20. The analyses for Src and its activation were
performed by ﬁxing cells for 10 min in 3% PFA, permeabilizing
for 2 min with 0.5% Triton X-100 and immunoreacting with
1:100 anti-pY416-p60Src and anti-npY527-p60Src Abs as well as
2 µg/ml anti-p60Src mAb. To investigate the distribution of the
αvβ3 integrin, β8 integrin subunit, pY773β3 integrin subunit,
p125FAK, SMAD2 and its phosphorylation, the cells were ﬁxed
as previously reported (58,59). The cellswere then immunoreacted
for 2 h with 1:100 anti-αvβ3 integrin, anti-β8 and anti-pY773β3, and
1:300 anti-SMAD2mAbs, andwith 1:100 anti-pSMAD2 (Ser465/467)
and anti-p125FAK Abs. To detect the membrane-associated in-
soluble fraction of CTGF, 48 h grown control and ATS ﬁbroblasts
were incubated in prechilled 1% Triton X-100 on ice for 20 min,
washed in PBS/0.15 M glycine, ﬁxed in 3% PFA for 7 min, blocked
in 1% BSA and immunoreacted for 1 h at room temperature (RT)
with 1:50 anti-CTGFAb (34). The analysis of p38 and its T180/Y182
phosphorylation was performed on cells ﬁxed in cold methanol,
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permeabilized for 1 h and immunoreactedwith 2.5 µg/ml anti-p38
mAbor 5.0 µg/ml anti-pT180/Y182-p38Ab. Afterwashing in PBS, the
cells were incubated for 1 h with the Alexa Fluor® 488 anti-rabbit
and Alexa Fluor® 594 anti-mouse secondary Abs or the rhoda-
mine-conjugated anti-goat IgG. The IF signals were collected
using aCCDblack andwhite TV camera (SensiCam-PCOComputer
Optics GmbH, Germany) mounted on a Zeiss ﬂuorescence-Axio-
vert microscope and digitalized using the Image Pro Plus program
(Media Cybernetics, Silver Spring, MD). The experiments were
repeated three times.
To investigate β3 integrin subunit co-distribution with
p125FAK, the Duolink in situ PLA probe and reagents (Olink® Bio-
science, Sigma Chemicals) were used in accordance with the
manufacturers’ instructions. In brief, control and ATS ﬁbroblasts
were grown on glass slides for 48 h, ﬁxed and immunoreacted ON
at +4°C as previously reported (58,59). The cellswere thenwashed
and incubated for 1 h at 37°C with the two PLA probes, the anti-
mouse MINUS probe and the anti-rabbit PLUS probe directed
against the anti-β3 mAb and anti-p125FAK Ab, respectively. The
two probes are secondary Abs that are labelled with an oligo-
nucleotide generating a ﬂuorescent signal only when they are
bound to the sample in close proximity. After removing the
probes and washing, the slides were incubated in a pre-heated
humidity chamber for 30 min at 37°C with ligase diluted 1:40 in
the ligation buffer containing the oligonucleotides that hybridize
to PLA probes. The slides were washed, reacted in the dark for
100 min at 37°C with 1:80 diluted polymerase, the rolling circle
ampliﬁcation was performed in the presence of ﬂuorophore-
labelled oligonucleotide probes, and the slidesmounted forﬂuor-
escent spot detection using microscopy.
ROS and LPO detection and ALDH activity measurement
To analyse the oxidative stress status in ATS versus control ﬁbro-
blasts, the ROS production was monitored using the CellROX®
Green Assay Kit (Molecular Probes® by Life Technologies), in ac-
cordancewith themanufacturers’ instructions. This kit efﬁcient-
ly detects the hydroxyl radical (OH−), superoxide anion (O2) and
TBHP. In brief, control, untransfected and transfected ATS ﬁbro-
blasts, grown for 48 h on a coverslide in completeMEM,were trea-
ted or not ON with increasing amounts, from 1.0 to 2.5 µ, of
PPARγ antagonist T0070907 (Sigma); the cells were then treated
with 500 n non-ﬂuorescent cell-permeable reduced CellROX®
reagent for 1 h at 37°C. Under these conditions, the CellROX®
reagent developed a ﬂuorogenic signal upon oxidation, which
indicated the presence of ROS in live cells. The ﬂuorescence de-
veloped by the ROS-mediated reaction was monitored in 3%
PFA-ﬁxed cells using microscopy with a 488 nm excitation ﬁlter.
Control ﬁbroblastswere treatedwith TBHP to induce the ROS pro-
duction as a positive control or with a mix of THBP and antioxi-
dant N-acetylcysteine (NAC) as a negative control.
To analyse the LPO process in ATS versus control ﬁbroblasts,
the Click-iT® LPO detection kit with LAA (Molecular Probes® by
Life Technologies) was used in accordance with the manufac-
turers’ instructions. In brief, the LAA substrate was incorporated
or not into the cells, grown for 48 h on a coverslide in complete
MEM.When LAA is oxidized, it produces hydroperoxides that de-
compose to unsaturated aldehydes, which modify proteins and
DNA. These modiﬁcations were detected through ﬁxing cells
with 3.7% PFA, permeabilizing with 0.5% Tween 20, blocking
with 1% BSA, and reacting for 30 min with the Click-iT® reaction
cocktail, which contains the Alexa Fluor 488 azide. Control ﬁbro-
blasts were treated with cumene hydroperoxide to induce LPO.
Labelling was monitored by ﬂuorescence microscopy.
To measure the ALDH enzyme activity, we used the ALDE-
FLUORTM detection kit in accordancewith themanufacturers’ in-
structions (STEMCELL Technologies, Vancouver, Canada). In
particular, control, untransfected and transfected ATS cells
were reacted for 1 h at 37°C with the ALDEFLUORTM Bodipy-con-
jugated aminoacetaldehyde (BAAA) reagent, which is a non-toxic
substrate that is converted into Bodipy-conjugated aminoacetate
in the presence of ALDH that is retained inside the cells. The
ﬂuorescence was monitored by ﬂow cytometry using the BD
FACSCanto™ Flow Cytometer and analysed using BD FACSDiva
Software 6.0 (BD Biosciences). In particular, the fold change of
ﬂuorescence greater than the background mean ﬂuorescence
measured without BAAA was calculated for all of the cell types;
the experiments were repeated three times. The results were ex-
pressed as RQ ofALDHactivity in ATS versus controls and in pG10
versus mock-transfected cells. Statistical analyses were per-
formed using GraphPad Prism software (***P < 0.0001). A speciﬁc
ALDH inhibitor, the diethylaminobenzaldehyde, was used as a
negative control.
Cell extracts and western blotting
To analyse the ALDH1A1 enzyme and CTGF, control, untrans-
fected and transfected ATS ﬁbroblastwere grown for 48 h in com-
plete MEM, washed twice in ice-cold PBS and extracted for 1 h at
+4°C with the RIPA buffer containing 150 m NaCl, 20 m Tris–
HCl, pH 7.4, 1% Nonidet P-40, 0.1% SDS, 1 m EDTA, 1 µg/ml leu-
peptin, 4 µg/ml pepstatin, 1 m PMSF, 1 m Na3VO4, 25 m NaF
and 10 m Na4P2O7. After scraping, the cell extracts were centri-
fuged at 14 000 rpm and +4°C for 12 min.
The PPARγ analysis was performed through scraping cells in
wash buffer (10 m PBS, 1 mNaF and 1 mNa3VO4), recovering
the cells after a 3000 rpm centrifugation and treating the cells at
+4°C for 1 h with agitation with a lysis buffer containing 50 m
KCl, 1% Nonidet P-40, 25 m HEPES, pH 7.8, 10 µg/ml leupeptin,
20 µg/ml aprotinin, 125 µ DTT, 1 m PMSF, 1 m Na3VO4 and
1 m NaF. The cell extracts were sonicated four times for 8 s
and centrifuged at 12 000 rpm and +4°C for 10 min.
The membrane-bound TGFBRI and TGFBRII analysis was per-
formed using the cell extracts obtained by lysing the cellswith 1%
Triton X-100, 0.1% SDS in 50 m Tris–HCl, pH 7.4, 150 m NaCl,
1 m EGTA, 1 m PMSF, 1 m NaF, 1 m Na3VO4, 1 µg/ml leu-
peptin and pepstatin, and 20 µg/ml aprotinin.
The integrin extractionwas performed by lysing the cells with
0.5% Triton X-100, 150 m NaCl, 1 m CaCl2, 1 mMgCl2, 20 m
Tris–HCl, pH 7.4, 1 m Na3VO4, 10 m NaF and 10 m Na4P2O7,
10 µg/ml leupeptin, 4 µg/ml pepstatin and 0.1 U/ml aprotinin.
The protein concentrationwas evaluated using detergent com-
patible Bio-Rad DC Protein Assay (Bio-Rad Laboratories, Hercules,
CA, USA); 20–50 μg of the total protein was separated by electro-
phoresis using 8% SDS–PAGE. After nitrocellulose sheet transfer,
the membranes were blocked ON at 37°C or at +4°C with 5% non-
fat dry milk (w/v) in TBS-0.1% Tween 20 (TBS-T) (blocking buffer)
and immunoreacted for 2 h at RT with 0.4 μg/ml anti-ALDH1A1
mAb or anti-CTGF Ab, with 1:1000 anti-TGFBRI and 1:500 anti-
TGFBRII Abs and with 1:1000 anti-PPARγ mAb or 2 μg/ml anti-
pS112-PPARγ Ab ON at +4°C and diluted in TBS-T. After washing in
TBS-T, themembranes were incubated for 2 h at RTwith HRP-con-
jugated anti-rabbit, anti-mouse or anti-goat IgGs, diluted in block-
ing buffer and developed using the ECLmethod (Pierce). The ﬁlters
were stripped, tested for the absence of a residual signal and re-
probedwith 1 μg/ml anti-β actinmAbdiluted in TBS-T for 2 h at RT.
To analyse tyrosine phosphorylation of TGFBRII and its co-
precipitation with β3 integrin subunit, 1 mg of TGFBR cell extract
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was immunoprecipitated with 10 µg of anti-TGFBRII Ab in ac-
cordance with the immunoprecipitation Dynabeads protein G
kit instructions (Novex by Life Technologies). The immuno-
complexes were tested through WB and immunoreacting with
anti-TGFBRII (1:500); 1:1000 anti-TGFBRI; anti-pY416-p60Src;
anti-pT180/Y182-p38 MAPK; and 1:1000 anti-PY20, anti-p38 MAPK
and anti-β3 integrin subunit mAbs.
To investigate the role of p60Src in p38 MAPK phosphoryl-
ation, the control, untransfected and transfected ATS P1 cells
were treated for 2 h with a subapoptotic dose (50 µM) of the spe-
ciﬁc Src family kinase inhibitor PP2 or its inactive analogue PP3
(Calbiochem), extracted for TGFBR, immunoprecipitated with
anti-TGFBRII Ab and immunoreacted with anti-TGFBRII and
anti-pT180/Y182-p38 Abs and anti-PY20 and anti-p38 mAbs, as re-
ported above. Alternatively, 1 mg of integrin cell extract was im-
munoprecipitatedwith 10 µg of anti-β3 integrin subunitmAb and
tested for co-immunoprecipitation of TGFBRII, TGFBRI and CTGF
by WB using the above conditions; of p125FAK through immu-
noreacting with 0.2 µg/ml anti-p125FAK Ab; and of p60Src using
1:1000 rabbit anti-p60Src mAb. Each experiment was performed
two times.
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